PPARG and rheumatoid arthritis: Genetic variation in the thiazolidinedione target (gene: PPARG) was significantly associated with a RA risk after multiple testing correction (OR 0.38 per 0.1mmol/L glucose lowering, 95%CI 0.20–0.73, P = 0.004; Fig. 2).